BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ORMD-0801 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ORMD-0801\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06731075-335@assetmemo.bio
DTSTAMP:20261121T004027Z
DTSTART;VALUE=DATE:20270425
DTEND;VALUE=DATE:20270426
SUMMARY:ORMD-0801: Phase 3 readout est. (NCT06731075)
DESCRIPTION:ORMD-0801\, phase 3\, Type 2 Diabetes.\nStudy: A Phase 3 Study 
 to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 D
 iabetes Mellitus.\nEstimated primary completion: 25 April 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ormd-0801#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06731075
URL:https://assetmemo.bio/drug/ormd-0801#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
